Navigation Links
Barr Announces Approval of Generic Camptosar(R) Injection, 20 mg/mL
Date:11/3/2008

MONTVALE, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pfizer Inc.'s Camptosar(R) (irinotecan hydrochloride) Injection, 20 mg/mL, packaged in 40 mg/2 mL and 100 mg/5 mL vials. The Company plans to launch its product in the fourth quarter of 2008. Barr's U.S. generic injectable portfolio now totals nine products.

Barr's generic version of Camptosar injection will compete in a market that had total annual sales of approximately $353 million for the twelve months ended August 2008, based on IMS sales data.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 27 proprietary products in the U.S. and approximately 1,025 products globally outside of the U.S. For more information, visit http://www.barrlabs.com.

Forward-Looking Statements

This communication contains "forward-looking statements" which represent the current expectations and beliefs of management of Barr Pharmaceuticals, Inc. (the "Company") concerning the proposed merger of the Company (the "merger") with Boron Acquisition Corp
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Pregis Announces Investor Conference Call to Review 2008 Third Quarter Financial Results
2. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
3. Insulet Announces Sponsorship of International Diabetes Federations World Diabetes Day Campaign
4. SXC Health Solutions announces PBM services agreement with Health Plan of San Mateo
5. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
6. China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results
7. Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information
8. Chindex International, Inc. Announces Preliminary Second Quarter Results and Improved Revenue Outlook for Fiscal 2009
9. Chindex International, Inc. Announces Appearances at Additional November Conferences
10. JZZ Technologies, Inc. Announces 3rd Quarter Results Date
11. Konica Minolta Sensing Americas Announces the Launch of the CM-SA Skin Analysis Software
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 1RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 2RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 3RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 4Injection Reverses Heart Attack Damage 4771 1Injection Reverses Heart Attack Damage 4771 2Injection Reverses Heart Attack Damage 4771 3Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 1Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 2Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 3
Other Medicine Technology:Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 2Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 3Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 4Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 5Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 6Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 2Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 3Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 4Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 5Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 6